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identified by Ignarro et al2 as nitric oxide (NO), a compound 
characterized in 1977 by Ferid Murad which caused smooth 
muscle cell relaxation, when released by nitrates. For this 
finding, Robert F. Furchgott, Ferid Murad and Louis J. Ignarro 
were awarded the Nobel Prize of Physiology or Medicine 
in 1998 (Figure 1). A series of studies was responsible for 
the demonstration that the endothelium releases other 
EDRF such as prostacyclin (PGI2), and the endothelium-
derived hyperpolarizing factor (EDHF), in addition to other 
endothelium-derived contracting factors (EDCF) such as 
endothelin (ET-1), cyclooxygenase pathway products such 
as thromboxane A2 (TXA2) and reactive oxygen species such 
as the superoxide anion (O2
.-)3. In addition to characterizing 
the endothelium as a biological sensor capable of detecting 
any mechanical, physical or chemical stimulus - and respond 
to it - these findings raised the endothelium to the position 
of a multifunctional tissue that plays an important role in the 
homeostasis of all physiological systems. 
Nitric oxide and the cardiovascular system
NO, a gaseous molecule that acts in the signaling of 
different biological processes, is a free radical presenting an 
unpaired electron in the last layer and a half-life of 4 to 8 
seconds in oxygenated aqueous medium4,5. It is described as 
a labile gas, capable of free diffusion across cell membranes, 
a characteristic that enhances its high biological activity6. 
The multiple NO actions were further broadened by the 
confirmation that the vascular endothelium is an active 
organ and that its integrity promotes beneficial effects, 
such as antioxidant, anti-inflammatory, anticoagulant, and 
pro-fibrinolytic actions; inhibition of leukocyte adhesion 
and migration; inhibition of smooth muscle cell migration 
and proliferation; and inhibition of platelet aggregation 
and adhesion7. Thus, this atheroprotective setting is 
characterized by a harmony between substances released by 
the endothelium, in which NO is cited as one of the most 
relevant vasoactive compounds. Characterized as a systemic 
disorder that precedes atherosclerosis and its complications, 
endothelial dysfunction in atherosclerotic coronary arteries 
was first described by Ludmer et al8 and later related to the 
change in NO bioavailability9. 
In the current literature, it is agreed that the reduced 
NO biological activity, caused both by synthase reduction 
and by increased degradation due to oxidation stress, has 
been identified as the most relevant mechanism in the 
multifactorial process in endothelial dysfunction and in the 
participation in the main cardiovascular dysfunctions10. Thus, 
reductions in NO bioavailability and subsequent endothelial 
Summary
Nitric oxide (NO), primarily identified as an endothelium-
derived relaxing factor, is a free radical that signals different 
biological processes. The identification of NO synthase 
(NOS) isoforms and the subsequent characterization of the 
mechanisms of cell activation of the enzymes permitted the 
partial understanding of both the physiological interactions and 
of the mechanisms of the diseases in which NO is involved. 
Mainly expressed in the vascular endothelium, the endothelial 
NOS isoform (eNOS) plays an important role in the regulation 
of vascular reactivity and in the development and progression 
of atherosclerosis. The purpose of this review is to contextualize 
the reader about the eNOS structure and its mechanisms of cell 
activation. In view of the advances in molecular biology, we 
will also address the known mechanisms of gene expression 
regulation and the role of variants on the genetic code of 
eNOS associated with cardiovascular phenotypes. Although 
the importance of NO as an atheroprotective molecule is 
recognized, our focus will be the review of the literature on 
NO and its participation in the modulation of the muscle 
vasodilatation phenotype. 
Introduction
The primary evidence that the endothelium is an 
indispensable component in the regulation of the vascular 
tone emerged from experimental analyses demonstrating that, 
in the absence of this single layer of squamous epithelium, 
acetylcholine-induced vasodilatation did not occur. In that 
moment, Furchgott and Zawadzki1 documented the fact that, 
when stimulated, the endothelium had the capacity to release 
a vasoactive substance, which was named endothelium-
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Figure 1 - 1998 Nobel Prize winners in Physiology or Medicine. Source: Available at: <http://nobelprize.org>.
Robert F. Furchgott, Louis J. Ignarro and Ferid Murad were awarded the 
1998 Nobel Prize in Physiology or Medicine. The three pharmacologists were 
acknowledged for their valuable contribution related to the discovery that Nitric 
Oxide is a signaling molecule in the cardiovascular system.
dysfunction trigger, in the vascular environment, events such 
as tone alterations, thrombotic dysfunctions, smooth muscle 
cell (SMC) proliferation and migration, as well as leukocyte 
adhesion11. When endothelial dysfunction occurs, there 
is also an increased production of reactive oxygen species 
(ROS)12, and these can reduce endothelial NO availability via 
different pathways: direct NO inactivation by superoxide with 
peroxynitrite (ONOO-)13 formation; reduction in NO synthase 
expression and activity due to changes in their substrate or 
cofactors, and in the increase in asymmetric dimethylarginine 
(ADMA) levels14; and also endothelial NOS uncoupling caused 
by increased tetrahydrobiopterin (BH4) oxidation
15. 
The understanding of the complexity of endothelial 
function has improved, and the difficulty in studying each 
one of its components separately has been overcome. In 
this context, animal models able to reproduce endothelial 
dysfunction have been developed, thus enabling the system 
to work under conditions of low or high NO bioavailability, 
for instance. Additionally, studies in vivo in humans, using 
intra-arterial infusion of compounds with the potential of 
modulating endothelial-dependent or independent function, 
permitted the investigation of modulatory mechanisms on the 
vascular function under different physiological conditions and 
more prevalent diseases.
Nitric oxide synthases
NO enzymatic production from the amino acid L-arginine 
is mediated by a family of three nitric oxide synthases (NOS) 
codified by distinct genes16. The isoforms share 50%-60% 
homology in the amino acid sequence in the oxidase 
and reductase domains17. These isoforms have distinct 
characteristics that reflect their specific functions in vivo18.
Endothelial NO synthase (eNOS or NOS III; 7q35-36) and 
neuronal nitric oxide synthase (nNOS or NOS I; 12q24.2) have 
a mechanism of constitutive activation (cNOS). The inducible 
isoform (iNOS or NOS II; 17cen-q12) is expressed in abnormal 
cell processes such as heart failure19, after induction by 
cytokines and other inflammatory agents, which results in a high 
NO flow20,21. Endothelial NOS is mainly located in endothelial 
cell compartments named caveolae22, and is essential for 
keeping the baseline vascular tone. This tone is partly mediated 
by NO synthesis, a vasoactive compound that participates 
in blood flow regulation in the different vascular beds and, 
particularly, in the coronary blood flow23. The subcellular 
location of NO synthesis has a great influence on its biological 
activity. In the 1990’s, the initial identification of eNOS location 
in the caveolae in the cell plasma membrane provided the 
structural basis for the recognition of compartmentalization 
in the mechanisms of cell signaling promoted by NO. The 
subsequent observation that eNOS interacts directly with 
structural proteins of the caveola - the caveolins, provided 
biochemical evidence of the interaction between eNOS and 
caveola and its implication with numerous signaling molecules 
concentrated in this environment of the cell membrane24. A 
great number of evidences revealed that the caveolae are 
capable of recruiting numerous signaling molecules and to 
regulate their activities instead of acting as a simple support for 
cell exchange and transportation25. Thus, it has been described 
that eNOS is located inside the caveolae and is kept in a less 
active state via its interaction with caveolin-126. 
eNOS structure
eNOS functions as a dimer consisting of two identical 
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divided into two major domains: a C-terminal reductase 
domain, homologous to cytochrome P450 which contains 
binding sites for NADPH, flavine mononucleotide (FMN) 
and flavine adenine dinucleotide (FAD); and an N-terminal 
oxidase, which subtracts one electron from the L-arginine 
substrate and has binding sites for heme iron, for the 
tetrahydrobiopterin cofactor (BH4) and for L-arginine
20,21,27 
(Figure 2). The catalysis reaction of constitutive NOS involves 
two oxidation stages: L-arginine hydroxylation into NG-
hydroxy-L-arginine, followed by oxidation of this intermediate 
compound with utilization of one NADPH electron, thus 
forming L-citrulline and NO28. This reaction consumes 1.5 
mol of NADPH and 2 moles of oxygen per mol of L-citrulline 
formed16,29,30. Cofactors such as heme iron, BH4 and L-arginine 
have been studied in depth, and their low bioavailability 
induces the phenomenon of dysfunctional eNOS31-33. Heme 
iron is essential for dimerization of the three isoforms34: low 
concentrations or absence of L-arginine catalyze oxygen 
reduction in superoxide (O2
.-)35, and decreased levels of BH4 
lead to the simultaneous production of NO e O2
.-, products 
that react with each other forming peroxynitrite (ONOO-)36.
Regulation of eNOS activity and gene 
expression
Ever since it was verified that the endothelial cells contain 
a baseline concentration of eNOS protein, the eNOS gene 
was considered constitutively expressed. Interestingly, further 
studies demonstrated that stable mRNA concentrations are 
subject to a modest level of regulation37. The eNOS gene 
promoter was cloned, and it was demonstrated that it has a 
complex regulatory mechanisms of gene expression. Like the 
promoter of constitutively expressed genes, the eNOS gene 
promoter does not contain the TATA box sequence. However, 
it has multiple cis-regulatory DNA sequences, including CCAT 
box, Sp1 sites, GATA motifs, CACCC box, AP-1 and AP-2 
sites, p53 binding sites, and NF-1 elements, in addition to 
sequences responsive to sterol elements and shear stress38. 
Bovine and human promoter sequences have a homology 
of 75%, thus suggesting a high evolutionary preservation of 
the gene transcriptional regulation. Located in the proximal 
promoter, the positive regulatory domains I and II (PRD I 
and PRD II) are involved in the baseline regulation of gene 
Figure 2 - A) Model proposed for the dimeric eNOS structure. B) Electron transfer between cofactors and substrates of the enzyme structure. The electron flows in 
the direction NADPH → FAD → FMN in the reductase domain of one monomer to Fe in the oxidase domain of the contralateral monomer. In figure A, observe that 
electron flow and arginine catalysis are shown in only one side of the enzyme. Electron transfer from one domain to another is mediated by calmodulin, which justifies 
the need for its linking to the recognition site for enzyme activation and subsequent NO synthesis. FAD - flavine adenine dinucleotide; FMN - flavine mononucleotide; 
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transcription, showing an affinity with the transcription factors 
Sp-1, Sp-3, Ets-1, Elf-1, YY1 and MYC-associated zinc finger 
protein39. Studies in vitro demonstrated that eNOS promoter 
responsiveness to shear stress is dependent on sequences 
located between -1,000 and -975, a region relative to 
transcription start40,41. Besides, the binding of NF-κβ subunits 
p50 and p65 to the responsive element GAGACC (-990; -984) 
- located upstream of the transcription start site, is involved 
in shear stress activation of the promoter42. Also, transcription 
in bovine endothelial cells subject to laminar flow showed 
a nine-fold increase in mRNA. This effect was mediated 
by two distinct mechanisms: 1) transient increase in gene 
transcription, and 2) subsequent prolonged mRNA half-life43.
The mechanism of eNOS activation has been described 
as the most elaborated of the free isoforms, reflecting 
the complexity of the physiologic control of the different 
vascular beds17,44. The classical mechanism of constitutive 
isoform activation is calcium (Ca++)-dependent, whereas 
iNOS is independent of the elevation of intracellular Ca++ 
concentrations, because of the high affinity of the enzyme 
binding with calmodulin31,39,44.
The complexity of the eNOS post-transcriptional regulatory 
mechanisms has been considered in the dimerization of the 
protein subunits and in the role of the protein caveolin in 
the formation of the caveolar structure45. Endothelial NOS is 
located inside the caveola and is kept in a less active state via 
its interaction with caveolin-126. The mechanisms migration 
from the cell membrane to the Golgi apparatus and Akt, PKA, 
and AMPK-kinase-dependent phosphorylations are described 
as responsible for the activation of this NOS isoform. Thus, 
the interaction keeps eNOS inactive, and calmodulin acts 
directly on the competition with caveolin in the promotion 
of the calcium-dependent enzyme activation15. Endothelial 
NOS activity is well known in the vascular environment, 
and is regulated by six mechanisms after its translation: 
lipid inclusion; calcium/modulin-dependent mechanism; 
direct protein-protein interactions; several phosphorilations; 
glycosylation; and substrate and cofactor availability. Thus, 
eNOS can interact with several proteins in their “less active” 
or “more active” states. The plasmalemma-bound eNOS 
N-myristoylation and palmitoylation processes are required, 
which, in this state, is associated with caveolin-1 and HSP 
90. The protein that interacts with HSP70, named “CHIP”, 
interacts with both HSP70 and HSP90, and downregulates 
eNOS traffic to the Golgi apparatus, in contrast to “NOSIP” 
and “NOSTRIN” which can downregulate eNOS location in 
the plasma membrane. The main eNOS activation mechanism 
occurs via phosphorylation of the amino acid serine at position 
1.17746 by the Akt-kinase enzyme (or kinase protein B), 
which increases eNOS sensitivity to baseline Ca++/calmodulin 
concentrations47. Tonic or phasic eNOS activation in response 
to blood flow is independent of Ca++ concentration changes 
and constitutes the shear stress. Dimmeler et al48 demonstrated 
that the exchange of the serine1177/1179 residue for the 
amino acid alanine makes eNOS incapable of responding 
to phosphorylation and activation by the Akt enzyme, a 
phosphatidylinositol-3-kinase (PI-3K)-dependent pathway. 
Although phosphorylation of the serine1177 residue plays 
a pivotal role in eNOS enzyme activation, its regulation is 
known to be also dependent on the phosphorylation pattern 
of other currently well-characterized sites49. Phosphorylation 
of the serine633 residue, located in the binding domain of 
flavine mononucleotide (FMN) also increases eNOS activity 
and seems to be particularly important to keep NO synthesis 
after serine1177 residue phosphorylation and activation by 
Ca++/calmodulin. Phosphorylated by protein kinase C (PKC), 
the threonin495 residue interferes with the calmodulin binding 
domain, thus downregulating NO synthesis.
Recent studies have evaluated the capacity of certain drugs, 
such as antioxidants and renin-angiotensin system blockers, 
to reduce endothelial dysfunction by means mechanisms of 
eNOS activation via phosphorylation of specific sites such as 
the serine1177 residue. This phosphorylation may be affected 
by the subcellular enzyme location, such as the caveolae, 
intercellular junctions, Golgi apparatus, and cytosolic 
compartments, as well as by protein kinases and phosphatases 
associated with these structures. Recently, our group50 
demonstrated that Telmisartan, an angiotensin II receptor 
blocker, promotes reduction of endothelial dysfunction by 
means of eNOS activation via phosphorylation of specific 
sites, such as serine1177 and serine635 residues. 
Nitric oxide, vascular tone and muscle 
vasodilatation
After confirmation that NO is synthesized by endothelial 
cells and that it participates in the cardiovascular hemodynamic 
regulation, interest was focused on the quantification of its 
participation in this homeostasis of this system. Studies in 
vivo in healthy individuals demonstrated that the intra-arterial 
administration of NG-monomethyl-L-arginine (L-NMMA) - an 
unspecific NOS activity blocker, reduces local blood flow 
by 25% to 50%51. Although the baseline vascular tone is the 
product of vasoconstrictor versus vasodilator forces, these 
results demonstrate that NO is, at least in part, the modulator 
of the phenotype at issue. 
During exercise and mental stress conditions, in addition 
to the tachycardic response and blood pressure increase, 
vasodilatation in the skeletal muscle bed is also observed as 
part of the physiological responses of body adjustment. It was 
hypothesized that part of this muscle vasodilator response 
would be modulated by a neural component, and this was 
later evidenced by the existence of cholinergic sympathetic 
fibers in the skeletal muscles of some mammal species, 
except for primates and humans. Electrical stimulation of 
the sympathetic nerve was verified to lead to vasodilatation 
in the human muscle bed when presynaptic norepinephrine 
release was inhibited by intra-arterial drug infusion. However, 
this vasodilator response was attenuated when a muscarinic 
antagonist was administered52,53. Later, it was evident that NO 
is, at least in part, the modulator of the vasodilator response 
verified when cholinergic sympathetic fibers are stimulated54. In 
fact, Blair et al55 had already shown that forearm vasodilatation 
in humans during physiologic maneuvers is mediated by 
a neural component. During application of mental stress, 
blood flow in the sympathectomized limb did not change in 
comparison to the blood flow in the control limb. In addition, 
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the increase in blood flow by approximately 50%. At that 
moment, using indirect evidence, the authors suggested the 
existence of cholinergic sympathetic enervation in the skeletal 
musculature of humans. Mimicking animal experiments, 
Dietz et al’s studies56,57 later showed that part of the muscle 
vasodilator response, as measured in the forearm during 
exercise or mental stress, is attenuated by the intra-arterial 
administration of L-NMMA. The mechanisms through which 
acetylcholine and NO are synthesized and released during the 
body defense reactions in humans are still not fully understood. 
Evidences obtained with pharmacological blockade permit 
only the suggestion of the existence of cholinergic sympathetic 
fibers in the skeletal musculature. Due to these limitations, 
the authors do not rule out the possibility of vasodilatation 
being caused by a combination between circulating and local 
factors. A small part of endothelial cells could synthesize 
and release acetylcholine58. In addition, activation of β2-
adrenergic receptors located in the vascular smooth muscle 
would result in relaxation of this tissue and, consequently, in 
vasodilatation. However, Majmudar et al59 verified that part 
of the vasodilatation resulting from β2-adrenoceptor activation 
is mediated by NO. Although the authors do not explain the 
mechanism responsible for this phenomenon, approximately 
25% of the vasodilatation observed in the forearm with 
infusion of Ritodrine (a selective β2-adrenergic agonist) was 
attenuated with the concomitant administration of L-NMMA. 
These results suggest the existence of β2-adrenoceptors in the 
vascular endothelium, thus contributing to the increase in 
eNOS activity. In addition, increased mechanical stimulation 
of the vascular endothelium would result in increased NO 
synthesis via PI-3K-Akt kinase, with subsequent serine1177 
residue phosphorylation.
eNOS polymorphisms and functional 
studies on the G894T variant
Genotyped and sequenced in 1993 by Marsden et al38 
(GenBank D26607), eNOS is located in chromosome 7q35-
36, and variations in its sequence have been described in the 
promoter, exons and introns27. The gene (21-22 kbp) comprises 
26 exons and 25 introns with 133 kDa. The polypeptide 
sequence generated contains 1,203 amino acids38. The 
existence of three single nucleotide polymorphisms (SNP) 
in the promoter, in non-binding locations of transcription 
factors has already been described in the literature39. SNP 
were found in introns 2, 11, 12, 18, 22 and 2360, and repeat 
sequence polymorphisms in introns 2, 4, 8, and 1338,61. Of 
the polymorphisms found in exons 6 and 7, replacement of 
the nitrogenous base guanine for thymine (G→T) at position 
894 located in exon 7 results in a change of the amino acid 
glutamate (GAG) to aspartate (GAT) at position 298 of the 
polypeptide sequence62. It is suggested that polymorphisms 
located in the gene promoter have an influence on mRNA 
transcription, whereas polymorphisms located in coding 
regions may result in changes in enzymatic activity63.
Residue 298 is located outside in the oxidase domain of the 
enzyme, binding sites for L-arginine or BH4. Enzymatic studies 
using recombinant eNOS showed no difference in Michaelis 
constant (km) or in Vmax between the two enzyme forms
63. 
Although the enzymatic activity is seemingly not affected by 
the Asp298 form of the enzyme, Tesauro et al64 showed that this 
variant is more susceptible to proteolytic cleavage into 100 and 
35 KDa fragments, more precisely in position Asp298-Pro299, 
in comparison to the Glu298 variant. However, Fairchild et 
al65 demonstrated that this proteolytic susceptibility occurred 
because of an artifact of the sample preparation method. The 
inconsistency of these results does not rule out the possibility 
that an unknown proteolytic mechanism or even a change 
in post-transcriptional regulation may be modulated by the 
Asp298 variant of the enzyme in vivo. 
Association between the G894T variant 
of the eNOS gene and cardiovascular 
phenotypes
Several diseases have been associated with abnormalities 
in NO biosynthesis, and many of these conditions are related 
to autonomic dysfunction. Population genetics studies 
have demonstrated a significant association of eNOS gene 
G894T polymorphism with coronary artery disease (CAD)66-
68 and also with acetylcholine (Ach)-induced coronary 
vasospasm69. Among the cardiovascular dysfunctions, the 
G894T variant was also demonstrated to be associated with 
hypertension70,71, although this association had not been 
verified in other populations72,73.
The correlation between genotype and clinical phenotype 
varies both quantitatively and qualitatively, and the 
inconsistent association between eNOS polymorphism and 
several clinical phenotypes is a phenomenon commonly 
observed in other phenotype-associated genes27. This 
inconsistency has been attributed to environmental factors, 
independent alleles, interaction between genes and variability 
in clinical phenotypes. The importance of environmental 
factors in the genesis of diseases is reflected in morbidity 
and mortality differences between genetically homogeneous 
groups, however with different life styles.
A genetic variation may not be relevant to a determined 
population, thus reflecting differences in the frequency 
of allele distribution. One example is the frequency of 
the allele 894T, which is significantly higher in white 
populations in comparison to the Japanese population23. 
The inconsistent association between eNOS polymorphism 
and vascular changes is still being attributed to the variation 
in eNOS distribution in different organs. Arteries of specific 
organs are subject to different hemodynamic pressures, 
determining the vessel wall response and subsequent degree 
of endothelial dysfunction27.
Philip et al62 studied patients undergoing surgical 
revascularization and observed that vascular reactivity to 
phenylephrine (PE) infusion is influenced by the G894T variant 
of the eNOS gene. The dose-dependent vasoconstrictor 
response to PE was significantly greater for the TT and GT 
alleles in comparison to the homozygote GG group, thus 
indicating that vascular reactivity to vasoconstrictor drugs 
may be influenced by eNOS polymorphism in humans. 
The greater dose-dependent response of patients with the 
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administration of NG-nitro-L-arginine methyl esther (L-NAME) 
leads to hypertension in humans74,75. According to Frandsenn 
et al76, the administration of 4mg/kg of L-NAME in humans 
reduces eNOS activity by 67%. The possibly reduced NO 
bioavailability subsequent to eNOS gene variations is an 
important candidate to the susceptibility to the development 
of endothelial dysfunction62,63 and changes in modulation of 
the sympathetic nervous activity on the vessel77.
Studies demonstrating the association between the G894T 
variant of the eNOS gene and cardiovascular phenotypes point 
to a possible reduction in NO bioavailability, thus suggesting 
that eNOS transcribed from the mutant allele has an abnormal 
enzymatic activity. The lack of evidence supporting this 
rationale encouraged us to test the functionality of the genetic 
variant on the muscle vasodilatation phenotype78. If the G894T 
variant of the eNOS gene could reduce the enzymatic activity, 
individuals with the mutant allele (T) would show a smaller 
increase in muscle blood flow in response to the handgrip 
isometric exercise. In order to test this hypothesis, 287 
individuals were genotyped; from these, 33 healthy individuals 
were selected to represent three genotypes: GG (wild type), 
GT and TT. The results showed that attenuated reflex muscle 
vasodilatation in response to exercise occurred only in the 
TT genotype, since vasodilatation among heterozygotes (GT 
genotype) was similar to that observed among homozygotes 
for the G allele (GG genotype). These results suggest that the 
presence of the G allele is sufficient to overcome a possible 
T allele deficiency. Subsequent analyses in vivo proved that 
the attenuated muscle vasodilatation observed in the TT 
genotype is a consequence of the reduced eNOS-mediated 
vasodilatation, since intra-arterial L-NMMA infusion did not 
change the vasodilator response to exercise in this genotype. 
In contrast, L-NMMA significantly reduced the vasodilator 
response to exercise in the GG genotype to values similar 
to those of the TT genotype. Also, our study demonstrated 
that the attenuated muscle vasodilatation observed in the 
TT genotype may not be accounted to a possibly increased 
vasoconstrictor sympathetic tone. In fact, the muscle 
sympathetic nervous activity, as measured directly in the fibular 
nerve using the microneurography technique, increased in a 
similar fashion among the genotypes during exercise. Although 
these results do not confirm the functionality of the T allele 
in the alteration of the enzymatic activity (this variant may be 
in linkage disequilibrium with other functional variant on the 
same gene or on a nearby gene on the same chromosome), 
they may be used as a marker of the dysfunction observed 
in the muscle vasodilatation phenotype. This is the first 
demonstration that the G894T variant of the eNOS gene 
is functionally associated with reduced eNOS-mediated 
vasodilatation. Also, these results suggest that the reduced 
endothelium-dependent vasodilatation may anticipate 
vascular dysfunction in individuals with the TT-genotype.
Conclusion
NO synthases were proven to be constitutively expressed 
(eNOS and nNOS) and NO plays an important role in the 
regulation of cardiovascular activities. These facts aroused the 
interest for the understanding of the molecular and cellular 
mechanisms that regulate their functionality. Although these 
mechanisms are complexo and difficult to access, some of 
them have already been elucidated, thus permitting partial 
knowledge of the NO biology. In this context, the advances 
in molecular biology techniques enabled the identification 
of variants in the human genetic code that could, at least in 
part, explain the phenotypical response variation between 
individuals. Genetic association studies are not easy to 
understand. A single gene may have a small to moderate 
participation in the regulation of a multigenic phenotype and, 
in this situation, a determinate functional genetic variant in 
this gene would explain only a small part of the phenotype 
response variation. The screening of candidate genes, that 
is, the identification of multiple genes and their respective 
polymorphisms which trigger variations in the cardiovascular 
function leads to the moment when part of the diagnosis and 
management adopted for the treatment will be based on 
genomic medicine. 
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